Carl Weissman

ISB Accelerator Corp. is involved in the study of biological systems to help identify strategies for predicting and preventing diseases such as cancer, diabetes and AIDS. The company is located in Seattle, WA.

Accelerator Services Corp (Accelerator Services) is a venture capital firm founded in 2003 by Carl Weissman and Rodney F. Burgar. The firm is headquartered in Seattle, Washington.

Homestead Clinical Corp. develops pharmaceutical products. It develops diagnostic, prognostic, and theranostic tools which is used for the diseases such as cancer, diabetes, and AIDS. The company was founded by Leroy E. Hood in June 2005 and is headquartered in Seattle, WA.

MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts.

Novomer, Inc. manufactures biodegradable plastics, polymers, and other chemicals from renewable substances. It specializes in commercializing a family of low-cost, high-performance, sustainable polymers and other chemicals. The company was founded by Geoffrey William Coates, Anthony Romey Eisenhut and Scott D. Allen in 2004 and is headquartered in Waltham, MA.

Acylin Therapeutics, Inc. develops drugs for cancer. The company was founded by Philip A. Cole, Peter S. DiStefano, Ronen Marmorstein, Suresh K. Jain and Roydon Price in 2009 and is headquartered in Seattle, WA.

Viral Logic Systems Technology Corp. provides pharmaceutical products and services. It develops treatments for autoimmune, inflammatory diseases and disorders. The company was founded by Steven R. Wiley and Craig A. Smith in 2004 and headquartered in Seattle, WA.

Groove Biopharma Corp. focuses on the generation of novel microRNA (miRNA) therapeutics with improved properties, including higher potency and enhanced pharmacodynamic activity. Endogenous microRNAs (miRNAs) were involved in extensive regulatory networks for many target genes and pathways. Groove Biopharma's core technology addressed a new avenue of nucleotide therapeutic drug discovery via modulation of cellular mirna. Used exclusive technology, Groove Biopharma were generated a series of lead candidates with the potential to be best-in-class therapeutics. By incorporated proprietary structural modifications into miRNA therapeutics, the Groove Biopharma technology platform presented promising potential for treating a wide range of diseases, including cancer, fibrosis, and infectious disease.The company was founded in 2008 and is headquartered in Seattle,UN.